196 related articles for article (PubMed ID: 2125837)
1. Encainide--an updated safety profile.
Thomis JA
Cardiovasc Drugs Ther; 1990 Jun; 4 Suppl 3():585-94. PubMed ID: 2125837
[TBL] [Abstract][Full Text] [Related]
2. Preliminary report: effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction.
Cardiac Arrhythmia Suppression Trial (CAST) Investigators
N Engl J Med; 1989 Aug; 321(6):406-12. PubMed ID: 2473403
[TBL] [Abstract][Full Text] [Related]
3. Effects of encainide, flecainide, imipramine and moricizine on ventricular arrhythmias during the year after acute myocardial infarction: the CAPS.
Cardiac Arrhythmia Pilot Study (CAPS) Investigators
Am J Cardiol; 1988 Mar; 61(8):501-9. PubMed ID: 2894169
[TBL] [Abstract][Full Text] [Related]
4. Interaction of baseline characteristics with the hazard of encainide, flecainide, and moricizine therapy in patients with myocardial infarction. A possible explanation for increased mortality in the Cardiac Arrhythmia Suppression Trial (CAST).
Anderson JL; Platia EV; Hallstrom A; Henthorn RW; Buckingham TA; Carlson MD; Carson PE
Circulation; 1994 Dec; 90(6):2843-52. PubMed ID: 7994829
[TBL] [Abstract][Full Text] [Related]
5. Proarrhythmia, cardiac arrest and death in young patients receiving encainide and flecainide. The Pediatric Electrophysiology Group.
Fish FA; Gillette PC; Benson DW
J Am Coll Cardiol; 1991 Aug; 18(2):356-65. PubMed ID: 1906902
[TBL] [Abstract][Full Text] [Related]
6. Implications of the Cardiac Arrhythmia Suppression Trial for antiarrhythmic drug treatment.
Bigger JT
Am J Cardiol; 1990 Feb; 65(8):3D-10D; discussion 68D-71D. PubMed ID: 2106253
[TBL] [Abstract][Full Text] [Related]
7. Events in the Cardiac Arrhythmia Suppression Trial (CAST): mortality in the entire population enrolled.
Epstein AE; Bigger JT; Wyse DG; Romhilt DW; Reynolds-Haertle RA; Hallstrom AP
J Am Coll Cardiol; 1991 Jul; 18(1):14-9. PubMed ID: 1904891
[TBL] [Abstract][Full Text] [Related]
8. Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial.
Echt DS; Liebson PR; Mitchell LB; Peters RW; Obias-Manno D; Barker AH; Arensberg D; Baker A; Friedman L; Greene HL
N Engl J Med; 1991 Mar; 324(12):781-8. PubMed ID: 1900101
[TBL] [Abstract][Full Text] [Related]
9. Mortality in patients treated with flecainide and encainide for supraventricular arrhythmias.
Pritchett EL; Wilkinson WE
Am J Cardiol; 1991 May; 67(11):976-80. PubMed ID: 1902055
[TBL] [Abstract][Full Text] [Related]
10. Treatment of ventricular arrhythmias after CAST.
Tonkin AM
Med J Aust; 1992 Apr; 156(7):488-92. PubMed ID: 1372950
[TBL] [Abstract][Full Text] [Related]
11. Circadian pattern of arrhythmic death in patients receiving encainide, flecainide or moricizine in the Cardiac Arrhythmia Suppression Trial (CAST).
Peters RW; Mitchell LB; Brooks MM; Echt DS; Barker AH; Capone R; Liebson PR; Greene HL
J Am Coll Cardiol; 1994 Feb; 23(2):283-9. PubMed ID: 8294678
[TBL] [Abstract][Full Text] [Related]
12. Predicting mortality after myocardial infarction from the response of RR variability to antiarrhythmic drug therapy.
Bigger JT; Rolnitzky LM; Steinman RC; Fleiss JL
J Am Coll Cardiol; 1994 Mar; 23(3):733-40. PubMed ID: 7509355
[TBL] [Abstract][Full Text] [Related]
13. Mortality following ventricular arrhythmia suppression by encainide, flecainide, and moricizine after myocardial infarction. The original design concept of the Cardiac Arrhythmia Suppression Trial (CAST).
Epstein AE; Hallstrom AP; Rogers WJ; Liebson PR; Seals AA; Anderson JL; Cohen JD; Capone RJ; Wyse DG
JAMA; 1993 Nov; 270(20):2451-5. PubMed ID: 8230622
[TBL] [Abstract][Full Text] [Related]
14. The Cardiac Arrhythmia Suppression Trial: first CAST ... then CAST-II.
Greene HL; Roden DM; Katz RJ; Woosley RL; Salerno DM; Henthorn RW
J Am Coll Cardiol; 1992 Apr; 19(5):894-8. PubMed ID: 1552108
[TBL] [Abstract][Full Text] [Related]
15. Events in the Cardiac Arrhythmia Suppression Trial (CAST): mortality in patients surviving open label titration but not randomized to double-blind therapy.
Wyse DG; Hallstrom A; McBride R; Cohen JD; Steinberg JS; Mahmarian J
J Am Coll Cardiol; 1991 Jul; 18(1):20-8. PubMed ID: 1904892
[TBL] [Abstract][Full Text] [Related]
16. The cardiac arrhythmia suppression trial (CAST).
Ruskin JN
N Engl J Med; 1989 Aug; 321(6):386-8. PubMed ID: 2501683
[No Abstract] [Full Text] [Related]
17. Safety of encainide for the treatment of ventricular arrhythmias.
Soyka LF
Am J Cardiol; 1986 Aug; 58(5):96C-103C. PubMed ID: 3092626
[TBL] [Abstract][Full Text] [Related]
18. Interaction of ischaemia and encainide/flecainide treatment: a proposed mechanism for the increased mortality in CAST I.
Greenberg HM; Dwyer EM; Hochman JS; Steinberg JS; Echt DS; Peters RW
Br Heart J; 1995 Dec; 74(6):631-5. PubMed ID: 8541168
[TBL] [Abstract][Full Text] [Related]
19. Events in the cardiac arrhythmia suppression trial: baseline predictors of mortality in placebo-treated patients.
Capone RJ; Pawitan Y; el-Sherif N; Geraci TS; Handshaw K; Morganroth J; Schlant RC; Waldo AL
J Am Coll Cardiol; 1991 Nov; 18(6):1434-8. PubMed ID: 1939943
[TBL] [Abstract][Full Text] [Related]
20. New antiarrhythmic drugs: tocainide, mexiletine, flecainide, encainide, and amiodarone.
Kreeger RW; Hammill SC
Mayo Clin Proc; 1987 Nov; 62(11):1033-50. PubMed ID: 3118116
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
